All In Biotech

Drug Trial Radar · NCT01477606

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication

Last checked: Nov 19, 2026Latest source record: Jun 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

451

Actual

Start

May 2012

Primary completion

Feb 26, 2020

Study completion Feb 26, 2020

Sponsor

Lead sponsor
University of UlmAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals
First posted
Nov 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, single-arm, open-label, multi-center study in adult patients with Acute Myeloid Leukemia (AML) and FLT3-ITD as defined in inclusion/exclusion criteria. The primary efficacy object is to evaluate the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival (EFS) in adult patients with AML exhibiting a FLT3-ITD. Sample size: 440 patients The treatment duration of an individual patient is between 18 and 24 months. Duration of the study for an individual patient including treatment (induction, consolidation \[chemotherapy or allogeneic SCT\], maintenance and follow-up period: Maximum 8 years

Conditions

  • Acute Myeloid Leukemia

Interventions

  • MidostaurinDrug

    Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle. Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy. Maintenance therapy: 50 mg oral twice daily over one year.

  • CytarabineDrug

    Induction therapy: 200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²) Consolidation therapy: Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2). Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2).

  • DaunorubicinDrug

    Induction therapy: 60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free SurvivalTime frame: 8years

Locations

55 sites in 2 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Krankenhaus der Barmherzigen Schwestern Linz

    Linz, Austria

  • Krankenhaus der Elisabethinen Linz GmbH

    Linz, Austria

  • Universitätsklinik für Innere Medizin III Salzburg

    Salzburg, Austria

  • Hanuschkrankenhaus Wien

    Vienna, Austria

  • Helios Klinikum Bad Saarow

    Bad Saarow, Germany

  • Vivantes Klinikum Neukölln

    Berlin, Germany

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Marienhospital Bochum-Herne

    Bochum, Germany

  • Medizinische Universitätsklinik Bochum

    Bochum, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Städtisches Klinikum Braunschweig gGmbH

    Braunschweig, Germany

  • Klinikum Bremen-Mitte gGmbH

    Bremen, Germany

  • Klinikum Darmstadt

    Darmstadt, Germany

  • Universitätsklinkum Düsseldorf

    Düsseldorf, Germany

  • Kliniken Essen-Süd

    Essen, Germany

  • Klinik für Onkologie, Gastroenterologie und Allg. Innere Medizin Esslingen

    Esslingen am Neckar, Germany

  • Malteser Krankenhaus St. Franziskus Hospital Flensburg

    Flensburg, Germany

  • Medizinische Universitätsklinik Freiburg

    Freiburg im Breisgau, Germany

  • MVZ Osthessen

    Fulda, Germany

  • Klinik der Justus-Liebig-Universität Gießen

    Giessen, Germany

  • Wilhelm-Anton-Hospital gGmbH Goch

    Goch, Germany

  • Universitätsmedizin Göttingen

    Göttingen, Germany

  • Universitätsklinikum Eppendorf

    Hamburg, Germany

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Evangelisches Krankenhaus Hamm

    Hamm, Germany

  • Klinikum Region Hannover GmbH

    Hanover, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • SLK Kliniken Heilbronn GmbH

    Heilbronn, Germany

  • Universitätskliniken des Saarlandes

    Homburg/Saar, Germany

  • Städtisches Klinikum Karlsruhe

    Karlsruhe, Germany

  • Städtisches Krankenhaus Kiel GmbH

    Kiel, Germany

  • Caritas Krankenhaus Lebach

    Lebach, Germany

  • Klinikum Lippe-Lemgo

    Lemgo, Germany

  • Märkische Kliniken GmbH Lüdenscheid

    Lüdenscheid, Germany

  • Universitätsklinikum der Otto-von-Guericke Universität Magdeburg

    Magdeburg, Germany

  • Universitätsklinikum der Johannes Gutenberg-Universität Mainz

    Mainz, Germany

  • Johannes Wesling Klinikum Minden

    Minden, Germany

  • Klinikum Schwabing

    München, Germany

  • Klinikum rechts der Isar der TU München

    München, Germany

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.